Table 3.

Therapeutic procedures, length of follow-up, BCVA, and outcomes in 22 patients with GPA and ocular manifestations

TREATMENT Drug combinations: • ivGC + ivCYC • oGC + oCYC • oGC + scMTX • oGC + oMMF • oGC + ivRTX	REMISSION INDUCTION No. of patients (%) • 2 (9.1) • 9 (40.9) • 3 (13.6) • 3 (13.6) • 5 (22.7)	REMISSION MAINTENANCE No. of patients (%) • 0 • 4 (18.2) • 2 (9.1) • 2 (9.1) • 14 (63.6)
FOLLOW-UP	MEDIAN • 51 months	RANGE • 21–84 months
BCVA • Grade I (20/25 or better) • Grade II (20/30 to 20/40) • Grade III (20/50 to 20/160) • Grade IV (20/200 or worse)	AT DISEASE ONSET No. of patients (%) • OD 0 - OS 0 • OD 11 (50) – OS 12 (54.5) • OD 8 (36.4) – OS 8 (36.4) • OD 3 (13.6) – OS 2 (9.1)	AT LAST FOLLOW-UP No. of patients (%) • OD 3 (13.6)- OS 2 (9.1) • OD 12 (54.5) – OS 14 (63.6) • OD 4 (18.2) – OS 4 (18.2) • OD 3 (13.6) – OS 2 (9.1)
OUTCOMES	OPHTHALMOLOGIC OUTCOME No. of patients (%) • Persistent remission: 17 (77.3) • Patients who relapsed 1 to 3 times: 5 (22.7): ° Necrotizing scleritis: 2 (9.1) ° Ulcerative keratitis: 1 (4.5) ° Orbital disease: 1 (4.5) ° Optic neuropathy: 1 (4.5)	SYSTEMIC OUTCOME No. of patients (%) • Persistent remission: 14 (63,6) • Patients who relapsed 1 to 3 times: 7 (31.8): ° Ear, nose, throat: 3 (13.6) ° Pulmonary: 3 (13.6) ° Renal: 1 (4.5) • Opportunistic infections: 3 (13.6) • Bacterial infections: 4 (18.2) • Death: 3 (13.6) due to: ° Generalized sepsis: 1 (4.5) ° Pneumonia: 1 (4.5) ° Colon carcinoma: 1 (4.5)

BCVA best-corrected visual acuity, CYC cyclophosphamide, GC glucocorticoids, GPA granulomatosis with polyangiitis, iv intravenous, MMF mycophenolate mofetil, MTX methotrexate, o oral, RTX rituximab, sc subcutaneous